{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:32:07Z","timestamp":1772166727694,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["NIH P41 EB017183"],"award-info":[{"award-number":["NIH P41 EB017183"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["3D Print Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study reports on the development of a novel 3D procedure planning technique to provide pre-ablation treatment planning for partial gland prostate cryoablation (cPGA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty men scheduled for partial gland cryoablation (cPGA) underwent pre-operative image segmentation and 3D modeling of the prostatic capsule, index lesion, urethra, rectum, and neurovascular bundles based upon multi-parametric MRI data. Pre-treatment 3D planning models were designed including virtual 3D cryotherapy probes to predict and plan cryotherapy probe configuration needed to achieve confluent treatment volume. Treatment efficacy was measured with 6\u2009month post-operative MRI, serum prostate specific antigen (PSA) at 3 and 6\u2009months, and treatment zone biopsy results at 6\u2009months. Outcomes from 3D planning were compared to outcomes from a series of 20 patients undergoing cPGA using traditional 2D planning techniques.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty men underwent cPGA. The median age of the cohort undergoing 3D treatment planning was 64.8\u2009years with a median pretreatment PSA of 6.97\u2009ng\/mL. The Gleason grade group (GGG) of treated index lesions in this cohort included 1 (5%) GGG1, 11 (55%) GGG2, 7 (35%) GGG3, and\u00a01 (5%) GGG4. Two (10%) of these treatments were post-radiation salvage therapies. The 2D treatment cohort included 20 men with a median age of 68.5\u2009yrs., median pretreatment PSA of 6.76\u2009ng\/mL. The Gleason grade group (GGG) of treated index lesions in this cohort included 3 (15%) GGG1, 8 (40%) GGG2, 8 (40%) GGG3, 1 (5%) GGG4. Two (10%) of these treatments were post-radiation salvage therapies. 3D planning predicted the same number of cryoprobes for each group, however a greater number of cryoprobes was used in the procedure for the prospective 3D group as compared to that with 2D planning (4.10\u2009\u00b1\u20091.37 and 3.25\u2009\u00b1\u20090.44 respectively,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01). At 6\u2009months post cPGA, the median PSA was 1.68\u00a0ng\/mL and 2.38\u2009ng\/mL in the 3D and 2D cohorts respectively, with a larger decrease noted in the 3D cohort (75.9% reduction noted in 3D cohort and 64.8% reduction 2D cohort,\n                      <jats:italic>p<\/jats:italic>\n                      0.48). In-field disease detection was 1\/14 (7.1%) on surveillance biopsy in the 3D cohort and 3\/14 (21.4%) in the 2D cohort,\n                      <jats:italic>p\u2009=\u20090.056)<\/jats:italic>\n                      In the 3D cohort, 6\u2009month biopsy was not performed in 4\u00a0patients (20%) due to undetectable PSA, negative MRI, and negative MRI Axumin PET. For the group with traditional 2D planning, treatment zone biopsy was positive in 3\/14 (21.4%) of the patients,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.056.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>3D prostate cancer models derived from mpMRI data provide novel guidance for planning confluent treatment volumes for cPGA and predicted a greater number of treatment probes than traditional 2D planning methods. This study prompts further investigation into the use of 3D treatment planning techniques as the increase of partial gland ablation treatment protocols develop.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41205-020-00085-2","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T07:03:09Z","timestamp":1604386989000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["MRI guided procedure planning and 3D simulation for partial gland cryoablation of the prostate: a pilot study"],"prefix":"10.1186","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8441-6059","authenticated-orcid":false,"given":"Nicole","family":"Wake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew B.","family":"Rosenkrantz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel K.","family":"Sodickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hersh","family":"Chandarana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S.","family":"Wysock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,3]]},"reference":[{"key":"85_CR1","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s00330-013-2795-0","volume":"23","author":"F Bratan","year":"2013","unstructured":"Bratan F, Niaf E, Melodelima C, Chesnais AL, Souchon R, Mege-Lechevallier F, et al. Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol. 2013;23:2019\u201329.","journal-title":"Eur Radiol"},{"key":"85_CR2","doi-asserted-by":"publisher","first-page":"E171","DOI":"10.1111\/j.1464-410X.2011.10112.x","volume":"108","author":"J Haffner","year":"2011","unstructured":"Haffner J, Lemaitre L, Puech P, Haber GP, Leroy X, Jones JS, et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int. 2011;108:E171\u20138.","journal-title":"BJU Int"},{"key":"85_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.eururo.2015.06.005","volume":"69","author":"X Meng","year":"2016","unstructured":"Meng X, Rosenkrantz AB, Mendhiratta N, Fenstermaker M, Huang R, Wysock JS, et al. Relationship between Prebiopsy multiparametric magnetic resonance imaging (MRI), biopsy indication, and MRI-ultrasound fusion-targeted prostate biopsy outcomes. Eur Urol. 2016;69:512\u20137.","journal-title":"Eur Urol"},{"key":"85_CR4","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1016\/j.juro.2006.08.007","volume":"176","author":"A Villers","year":"2006","unstructured":"Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol. 2006;176:2432\u20137.","journal-title":"J Urol"},{"key":"85_CR5","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815\u201322.","journal-title":"Lancet"},{"key":"85_CR6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/jama.2014.17942","volume":"313","author":"MM Siddiqui","year":"2015","unstructured":"Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, et al. Comparison of MR\/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313:390\u20137.","journal-title":"JAMA."},{"key":"85_CR7","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378:1767\u201377.","journal-title":"N Engl J Med"},{"key":"85_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.juro.2016.07.084","volume":"197","author":"A Priester","year":"2017","unstructured":"Priester A, Natarajan S, Khoshnoodi P, Margolis DJ, Raman SS, Reiter RE, et al. Magnetic resonance imaging underestimation of prostate cancer geometry: use of patient specific molds to correlate images with whole mount pathology. J Urol. 2017;197:320\u20136.","journal-title":"J Urol"},{"key":"85_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11934-020-00987-y","volume":"21","author":"D Eldred-Evans","year":"2020","unstructured":"Eldred-Evans D, Tam H, Smith APT, Winkler M, Ahmed HU. Use of imaging to optimise prostate cancer tumour volume assessment for focal therapy planning. Curr Urol Rep. 2020;21:38.","journal-title":"Curr Urol Rep"},{"key":"85_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1148\/radiol.14140524","volume":"275","author":"F Bratan","year":"2015","unstructured":"Bratan F, Melodelima C, Souchon R, Hoang Dinh A, Mege-Lechevallier F, Crouzet S, et al. How accurate is multiparametric MR imaging in evaluation of prostate cancer volume? Radiology. 2015;275:144\u201354.","journal-title":"Radiology."},{"key":"85_CR11","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.juro.2015.02.080","volume":"194","author":"J Le Nobin","year":"2015","unstructured":"Le Nobin J, Rosenkrantz AB, Villers A, Orczyk C, Deng FM, Melamed J, et al. Image guided focal therapy for magnetic resonance imaging visible prostate cancer: defining a 3-dimensional treatment margin based on magnetic resonance imaging histology co-registration analysis. J Urol. 2015;194:364\u201370.","journal-title":"J Urol"},{"key":"85_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2016.08.044","volume":"71","author":"M Valerio","year":"2017","unstructured":"Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A, et al. New and established Technology in Focal Ablation of the prostate: a systematic review. Eur Urol. 2017;71:17\u201334.","journal-title":"Eur Urol"},{"key":"85_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.urolonc.2020.04.017","volume":"38","author":"E Becher","year":"2020","unstructured":"Becher E, Lepor H. Oncological control following partial gland ablation for intermediate-risk prostate cancer. Urol Oncol. 2020;38:671\u20137.","journal-title":"Urol Oncol"},{"key":"85_CR14","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1097\/JU.0000000000000456","volume":"202","author":"M Oishi","year":"2019","unstructured":"Oishi M, Gill IS, Tafuri A, Shakir A, Cacciamani GE, Iwata T, et al. Hemigland Cryoablation of localized low, intermediate and high risk prostate cancer: oncologic and functional outcomes at 5 years. J Urol. 2019;202:1188\u201398.","journal-title":"J Urol"},{"key":"85_CR15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.eururo.2018.12.030","volume":"76","author":"TT Shah","year":"2019","unstructured":"Shah TT, Peters M, Eldred-Evans D, Miah S, Yap T, Faure-Walker NA, et al. Early-medium-term outcomes of primary focal Cryotherapy to treat nonmetastatic clinically significant prostate cancer from a prospective multicentre registry. Eur Urol. 2019;76:98\u2013105.","journal-title":"Eur Urol"},{"key":"85_CR16","doi-asserted-by":"publisher","first-page":"e831","DOI":"10.1016\/j.clgc.2019.05.014","volume":"17","author":"A Aminsharifi","year":"2019","unstructured":"Aminsharifi A, Jibara G, Tsivian E, Tsivian M, Elshafei A, Polascik TJ. Salvage prostate Cryoablation for the Management of Local Recurrence after primary Cryotherapy: a retrospective analysis of functional and intermediate-term oncological outcomes associated with a second therapeutic freeze. Clin Genitourin Cancer. 2019;17:e831\u20136.","journal-title":"Clin Genitourin Cancer"},{"key":"85_CR17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.urolonc.2010.04.001","volume":"30","author":"JR Caso","year":"2012","unstructured":"Caso JR, Tsivian M, Mouraviev V, Polascik TJ. Predicting biopsy-proven prostate cancer recurrence following cryosurgery. Urol Oncol. 2012;30:391\u20135.","journal-title":"Urol Oncol"},{"key":"85_CR18","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.juro.2008.04.027","volume":"180","author":"JS Jones","year":"2008","unstructured":"Jones JS, Rewcastle JC, Donnelly BJ, Lugnani FM, Pisters LL, Katz AE. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. J Urol. 2008;180:554\u20138.","journal-title":"J Urol"},{"key":"85_CR19","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0090-4295(00)01060-8","volume":"57","author":"JP Long","year":"2001","unstructured":"Long JP, Bahn D, Lee F, Shinohara K, Chinn DO, Macaluso JN Jr. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology. 2001;57:518\u201323.","journal-title":"Urology."},{"key":"85_CR20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.urology.2017.10.029","volume":"112","author":"AB Barqawi","year":"2018","unstructured":"Barqawi AB, Huebner E, Krughoff K, O'Donnell CI. Prospective outcome analysis of the safety and efficacy of partial and complete Cryoablation in organ-confined prostate cancer. Urology. 2018;112:126\u201331.","journal-title":"Urology."},{"key":"85_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cryobiol.2013.11.001","volume":"68","author":"JG Baust","year":"2014","unstructured":"Baust JG, Gage AA, Bjerklund Johansen TE, Baust JM. Mechanisms of cryoablation: clinical consequences on malignant tumors. Cryobiology. 2014;68:1\u201311.","journal-title":"Cryobiology."},{"key":"85_CR22","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/j.joms.2015.04.038","volume":"73","author":"DM Steinbacher","year":"2015","unstructured":"Steinbacher DM. Three-dimensional analysis and surgical planning in Craniomaxillofacial surgery. J Oral Maxillofac Surg. 2015;73:S40\u201356.","journal-title":"J Oral Maxillofac Surg"},{"key":"85_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1080\/24699322.2016.1240235","volume":"21","author":"GY Wang","year":"2016","unstructured":"Wang GY, Huang WJ, Song Q, Qin YT, Liang JF. Computer-assisted virtual preoperative planning in orthopedic surgery for acetabular fractures based on actual computed tomography data. Comput Assist Surg (Abingdon). 2016;21:160\u20135.","journal-title":"Comput Assist Surg (Abingdon)"},{"key":"85_CR24","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1002\/mma.3548","volume":"39","author":"AEC Jaberzadeh","year":"2016","unstructured":"Jaberzadeh AEC. Pre-operative planning of multiple probes in three dimensions for liver cryosurgery: comparison of different optimization methods. Math Methods Appl Sci. 2016;39:4764\u201372.","journal-title":"Math Methods Appl Sci"},{"key":"85_CR25","first-page":"486","volume":"9","author":"I Altrogge","year":"2006","unstructured":"Altrogge I, Kroger T, Preusser T, Buskens C, Pereira PL, Schmidt D, et al. Towards optimization of probe placement for radio-frequency ablation. Med Image comput comput Assist Interv. 2006;9:486\u201393.","journal-title":"Med Image comput comput Assist Interv"},{"key":"85_CR26","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1109\/JBHI.2013.2287202","volume":"18","author":"H Ren","year":"2014","unstructured":"Ren H, Campos-Nanez E, Yaniv Z, Banovac F, Abeledo H, Hata N, et al. Treatment planning and image guidance for radiofrequency ablation of large tumors. IEEE J Biomed Health Inform. 2014;18:920\u20138.","journal-title":"IEEE J Biomed Health Inform"},{"key":"85_CR27","first-page":"676","volume":"10","author":"C Baegert","year":"2007","unstructured":"Baegert C, Villard C, Schreck P, Soler L. Multi-criteria trajectory planning for hepatic radiofrequency ablation. Med Image comput Comput Assist Interv. 2007;10:676\u201384.","journal-title":"Med Image comput Comput Assist Interv"},{"key":"85_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/10255840500289988","volume":"8","author":"C Villard","year":"2005","unstructured":"Villard C, Soler L, Gangi A. Radiofrequency ablation of hepatic tumors: simulation, planning, and contribution of virtual reality and haptics. Comput Methods Biomech Biomed Engin. 2005;8:215\u201327.","journal-title":"Comput Methods Biomech Biomed Engin"},{"key":"85_CR29","doi-asserted-by":"crossref","unstructured":"Wysock JS, Becher E, Gogaj R, Velazquez N, Lepor H. Early oncological control following partial gland cryo-ablation: a prospective experience specifying reflex MRI guided biopsy of the ablation zone. Prostate Cancer Prostatic Dis. 2020.","DOI":"10.1038\/s41391-020-0244-0"},{"key":"85_CR30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.eururo.2013.10.048","volume":"66","author":"JS Wysock","year":"2014","unstructured":"Wysock JS, Rosenkrantz AB, Huang WC, Stifelman MD, Lepor H, Deng FM, et al. A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial. Eur Urol. 2014;66:343\u201351.","journal-title":"Eur Urol"},{"key":"85_CR31","first-page":"145","volume":"20","author":"H Lepor","year":"2018","unstructured":"Lepor H, Gold S, Wysock J. Focal ablation of prostate cancer. Rev Urol. 2018;20:145\u201357.","journal-title":"Rev Urol"},{"key":"85_CR32","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00345-016-1811-9","volume":"34","author":"DA Duijzentkunst","year":"2016","unstructured":"Duijzentkunst DA, Peters M, van der Voort van Zyp JR, Moerland MA, van Vulpen M. Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review. World J Urol. 2016;34:1521\u201331.","journal-title":"World J Urol"},{"key":"85_CR33","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.crad.2016.02.012","volume":"71","author":"N Wake","year":"2016","unstructured":"Wake N, Chandarana H, Huang WC, Taneja SS, Rosenkrantz AB. Application of anatomically accurate, patient-specific 3D printed models from MRI data in urological oncology. Clin Radiol. 2016;71:610\u20134.","journal-title":"Clin Radiol"},{"key":"85_CR34","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00345-010-0554-2","volume":"28","author":"N Arumainayagam","year":"2010","unstructured":"Arumainayagam N, Moore CM, Ahmed HU, Emberton M. Photodynamic therapy for focal ablation of the prostate. World J Urol. 2010;28:571\u20136.","journal-title":"World J Urol"},{"key":"85_CR35","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/j.1464-410X.2012.11262.x","volume":"110","author":"ER Cordeiro","year":"2012","unstructured":"Cordeiro ER, Cathelineau X, Thuroff S, Marberger M, Crouzet S, de la Rosette JJ. High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer. BJU Int. 2012;110:1228\u201342.","journal-title":"BJU Int"},{"key":"85_CR36","first-page":"103","volume":"4","author":"B Djavan","year":"1998","unstructured":"Djavan B, Susani M, Shariat S, Zlotta AR, Silverman DE, Schulman CC, et al. Transperineal radiofrequency interstitial tumor ablation (RITA) of the prostate. Tech Urol. 1998;4:103\u20139.","journal-title":"Tech Urol"},{"key":"85_CR37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11934-010-0100-1","volume":"11","author":"M Tsivian","year":"2010","unstructured":"Tsivian M, Polascik TJ. Focal cryotherapy for prostate cancer. Curr Urol Rep. 2010;11:147\u201351.","journal-title":"Curr Urol Rep"},{"key":"85_CR38","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/pcan.2014.33","volume":"17","author":"M Valerio","year":"2014","unstructured":"Valerio M, Stricker PD, Ahmed HU, Dickinson L, Ponsky L, Shnier R, et al. Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2014;17:343\u20137.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"85_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.prnil.2015.03.007","volume":"3","author":"S Marshall","year":"2015","unstructured":"Marshall S, Taneja S. Focal therapy for prostate cancer: the current status. Prostate Int. 2015;3:35\u201341.","journal-title":"Prostate Int"},{"key":"85_CR40","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.compmedimag.2013.01.009","volume":"37","author":"M Kersten-Oertel","year":"2013","unstructured":"Kersten-Oertel M, Jannin P, Collins DL. The state of the art of visualization in mixed reality image guided surgery. Comput Med Imaging Graph. 2013;37:98\u2013112.","journal-title":"Comput Med Imaging Graph"},{"key":"85_CR41","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/bju.12548","volume":"114","author":"BG Muller","year":"2014","unstructured":"Muller BG, van den Bos W, Brausi M, Cornud F, Gontero P, Kirkham A, et al. Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project. BJU Int. 2014;114:698\u2013707.","journal-title":"BJU Int"},{"key":"85_CR42","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s00261-016-1022-2","volume":"42","author":"N Wake","year":"2017","unstructured":"Wake N, Rude T, Kang SK, Stifelman MD, Borin JF, Sodickson DK, et al. 3D printed renal cancer models derived from MRI data: application in pre-surgical planning. Abdom Radiol (NY). 2017;42:1501\u20139.","journal-title":"Abdom Radiol (NY)"}],"container-title":["3D Printing in Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s41205-020-00085-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s41205-020-00085-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s41205-020-00085-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T07:23:01Z","timestamp":1604388181000},"score":1,"resource":{"primary":{"URL":"https:\/\/threedmedprint.biomedcentral.com\/articles\/10.1186\/s41205-020-00085-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["85"],"URL":"https:\/\/doi.org\/10.1186\/s41205-020-00085-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.23583\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.23583\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.23583\/v1","asserted-by":"object"}]},"ISSN":["2365-6271"],"issn-type":[{"value":"2365-6271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,3]]},"assertion":[{"value":"11 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the NYU Langone Health Institutional Review Board (IRB). All patients signed written informed consent to participate.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors provided consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Financial Disclosures related to this work: none.Financial and Non-Financial Disclosures not related to this work:NW - In-Kind Research Support: Stratasys, Ltd. Consultant \u2013 GE Healthcare.ABR \u2013 Royalties, Thieme Medical Publishers, Inc.DKS \u2013 Royalties, General Electric Company License agreement, General Electric Company; Royalties, Bruker Corporation License agreement, Bruker Corporation; Research collaboration, Siemens AG.HC \u2013 Equipment support, Siemens AG; Software support, Siemens AG; Advisory Board, Siemens AG; Speaker, Bayer AG.No competing interests: JSW.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}